MedPath

Vinorelbine

Generic Name
Vinorelbine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C45H54N4O8
CAS Number
71486-22-1
Unique Ingredient Identifier
Q6C979R91Y
Background

Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .

It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .

Indication

Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .

For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .

For the treatment of recurrent or metastatic squamous cell head and neck cancer .

For the treatment of recurrent ovarian cancer .

For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .

For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .

Associated Conditions
Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
Associated Therapies
-

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

First Posted Date
2021-01-06
Last Posted Date
2024-08-09
Lead Sponsor
Seagen Inc.
Target Recruit Count
502
Registration Number
NCT04697628
Locations
🇺🇸

Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States

🇺🇸

Maryland Oncology Hematology, P.A., Columbia, Maryland, United States

🇮🇹

Fondazione Policlinico Universitario Agostino, Roma, Other, Italy

and more 189 locations

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

First Posted Date
2020-12-23
Last Posted Date
2020-12-23
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
71
Registration Number
NCT04681911
Locations
🇨🇳

Sun Yat Sen Memorial Hospital,Sun Yat sen University, Guangzhou, Guangdong, China

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Phase 3
Conditions
Breast Cancer
Interventions
First Posted Date
2020-12-14
Last Posted Date
2020-12-14
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
50
Registration Number
NCT04665986

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

First Posted Date
2020-11-12
Last Posted Date
2024-05-23
Lead Sponsor
University of Birmingham
Target Recruit Count
1672
Registration Number
NCT04625907
Locations
🇬🇷

University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece

🇮🇱

Rambam Health Care Campus, Haifa, Israel

🇮🇱

Hadassah University Medical Centre, Jerusalem, Israel

and more 125 locations

Evolutionary Therapy for Rhabdomyosarcoma

First Posted Date
2020-05-14
Last Posted Date
2024-12-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
28
Registration Number
NCT04388839
Locations
🇺🇸

Connecticut Children's Medical Center, Hartford, Connecticut, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States

and more 15 locations

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3
Conditions
Breast Cancer
Interventions
First Posted Date
2020-03-13
Last Posted Date
2020-03-13
Lead Sponsor
Fudan University
Target Recruit Count
316
Registration Number
NCT04307147
Locations
🇨🇳

Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

Phase 2
Recruiting
Conditions
Advanced Breast Cancer
Interventions
First Posted Date
2020-03-11
Last Posted Date
2023-06-28
Lead Sponsor
European Institute of Oncology
Target Recruit Count
162
Registration Number
NCT04304352
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Phase 2
Conditions
Breast Cancer
Interventions
First Posted Date
2020-03-10
Last Posted Date
2020-03-10
Lead Sponsor
Fudan University
Target Recruit Count
550
Registration Number
NCT04302441
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Phase 1
Recruiting
Conditions
Rhabdomyosarcoma
Interventions
First Posted Date
2020-03-06
Last Posted Date
2024-06-12
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
38
Registration Number
NCT04299113
Locations
🇺🇸

Rebecca Phelan, Los Angeles, California, United States

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Phase 2
Conditions
Breast Cancer
Interventions
First Posted Date
2020-03-05
Last Posted Date
2020-03-05
Lead Sponsor
Fudan University
Target Recruit Count
178
Registration Number
NCT04296162
Locations
🇨🇳

Zhi-Ming Shao, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath